Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Acadia Pharmaceutica (ACAD)

Acadia Pharmaceutica (ACAD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,554,224
  • Shares Outstanding, K 160,643
  • Annual Sales, $ 441,760 K
  • Annual Income, $ -281,580 K
  • 60-Month Beta 0.66
  • Price/Sales 5.74
  • Price/Cash Flow N/A
  • Price/Book 4.77
Trade ACAD with:

Options Overview

Details
  • Implied Volatility 66.15%
  • Historical Volatility 35.02%
  • IV Percentile 35%
  • IV Rank 27.13%
  • IV High 140.61% on 03/09/21
  • IV Low 38.43% on 06/03/21
  • Put/Call Vol Ratio 0.21
  • Today's Volume 473
  • Volume Avg (30-Day) 540
  • Put/Call OI Ratio 0.69
  • Today's Open Interest 11,673
  • Open Int (30-Day) 13,418

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.26
  • Number of Estimates 10
  • High Estimate -0.19
  • Low Estimate -0.32
  • Prior Year -0.54
  • Growth Rate Est. (year over year) +51.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
15.68 +2.81%
on 09/14/21
17.87 -9.79%
on 09/01/21
-0.72 (-4.28%)
since 08/16/21
3-Month
15.68 +2.81%
on 09/14/21
26.50 -39.17%
on 06/17/21
-9.78 (-37.76%)
since 06/16/21
52-Week
15.68 +2.81%
on 09/14/21
57.46 -71.95%
on 11/25/20
-23.08 (-58.88%)
since 09/16/20

Most Recent Stories

More News
Lifshitz Law Firm, P.C. Announces Investigations of 3D Systems Corp. (NYSE: DDD), Acadia Pharmaceuticals, Inc. (NasdaqGS: ACAD), ChemoCentryx, Inc. (NasdaqGS: CCXI), and Peloton Interactive, Inc (NasdaqGS: PTON)

EQNX::TICKER_START EQNX::TICKER_END

DDD : 30.63 (+1.76%)
ACAD : 16.12 (+1.38%)
CCXI : 15.99 (+0.06%)
PTON : 104.92 (-0.61%)
Acadia Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will present at the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021, at 3:00 p.m. Eastern Time.

ACAD : 16.12 (+1.38%)
ACADIA (ACAD) Q2 Earnings Beat, Revenues Miss Estimates

ACADIA's (ACAD) loss narrows in the second quarter of 2021 while its revenues miss the mark. The company has reduced its revenue guidance for 2021. Shares down in after-hours trading.

TECH : 529.46 (-0.03%)
ACAD : 16.12 (+1.38%)
SPRO : 19.05 (+2.81%)
COCP : 1.0800 (+1.89%)
Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Misses Revenue Estimates

Acadia (ACAD) delivered earnings and revenue surprises of 10.00% and -9.27%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

ACAD : 16.12 (+1.38%)
Acadia: Q2 Earnings Snapshot

SAN DIEGO (AP) _ Acadia Pharmaceuticals Inc. (ACAD) on Wednesday reported a loss of $43.9 million in its second quarter.

ACAD : 16.12 (+1.38%)
Acadia Pharmaceuticals Reports Second Quarter 2021 Financial Results

--- Fiscal year 2021 revenue guidance reduced to $480 to $515 million

ACAD : 16.12 (+1.38%)
The New England Journal of Medicine Publishes Results from the Phase 3 HARMONY Study Evaluating Pimavanserin in Patients with Dementia-Related Psychosis

--- Pimavanserin met the secondary endpoint of significantly reducing trial discontinuation for any reason by 2.2 fold

ACAD : 16.12 (+1.38%)
Acadia Pharmaceuticals to Announce Second Quarter 2021 Financial Results on August 4, 2021

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter 2021 financial results on Wednesday, August 4, 2021, after the close of the U.S. financial markets. Acadia's...

ACAD : 16.12 (+1.38%)
Cassava Sciences (SAVA) to Post Q2 Earnings: What's in Store?

Investors will be keen on updates from on its lead candidate, sumifilam, for Alzheimer's disease when Cassava (SAVA) reports Q2 results.

EXAS : 102.79 (-1.78%)
ACAD : 16.12 (+1.38%)
BPMC : 102.96 (-0.74%)
SAVA : 43.95 (+0.07%)
Synlogic's (SYBX) Begins Phase I Study for PKU Treatment

Synlogic (SYBX) initiates phase I study of SYNB1934, a synthetic biotic candidate to treat PKU. The drug is an evolved strain of SYNB1618, another PKU candidate currently undergoing phase II study.

BMRN : 76.50 (-1.00%)
EXAS : 102.79 (-1.78%)
ACAD : 16.12 (+1.38%)
SYBX : 3.19 (+0.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104...

See More

Key Turning Points

3rd Resistance Point 16.69
2nd Resistance Point 16.41
1st Resistance Point 16.26
Last Price 16.12
1st Support Level 15.84
2nd Support Level 15.56
3rd Support Level 15.42

See More

52-Week High 57.46
Fibonacci 61.8% 41.50
Fibonacci 50% 36.57
Fibonacci 38.2% 31.64
Last Price 16.12
52-Week Low 15.68

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar